KR102762958B1 - 위장관췌장 신경내분비 신생물의 진단을 위한 조성물, 방법 및 키트 - Google Patents

위장관췌장 신경내분비 신생물의 진단을 위한 조성물, 방법 및 키트 Download PDF

Info

Publication number
KR102762958B1
KR102762958B1 KR1020177010086A KR20177010086A KR102762958B1 KR 102762958 B1 KR102762958 B1 KR 102762958B1 KR 1020177010086 A KR1020177010086 A KR 1020177010086A KR 20177010086 A KR20177010086 A KR 20177010086A KR 102762958 B1 KR102762958 B1 KR 102762958B1
Authority
KR
South Korea
Prior art keywords
gep
nen
biomarkers
expression
test sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177010086A
Other languages
English (en)
Korean (ko)
Other versions
KR20170045365A (ko
Inventor
얼빈 마크 모들린
마크 키드
이그낫 드로츠도프
Original Assignee
클리프톤 라이프 사이언시즈 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 클리프톤 라이프 사이언시즈 엘엘씨 filed Critical 클리프톤 라이프 사이언시즈 엘엘씨
Priority to KR1020257003150A priority Critical patent/KR20250021631A/ko
Publication of KR20170045365A publication Critical patent/KR20170045365A/ko
Application granted granted Critical
Publication of KR102762958B1 publication Critical patent/KR102762958B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G01N33/57407—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/143—Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020177010086A 2014-09-15 2015-09-15 위장관췌장 신경내분비 신생물의 진단을 위한 조성물, 방법 및 키트 Active KR102762958B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257003150A KR20250021631A (ko) 2014-09-15 2015-09-15 위장관췌장 신경내분비 신생물의 진단을 위한 조성물, 방법 및 키트

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462050465P 2014-09-15 2014-09-15
US62/050,465 2014-09-15
PCT/US2015/050274 WO2016044330A1 (en) 2014-09-15 2015-09-15 Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257003150A Division KR20250021631A (ko) 2014-09-15 2015-09-15 위장관췌장 신경내분비 신생물의 진단을 위한 조성물, 방법 및 키트

Publications (2)

Publication Number Publication Date
KR20170045365A KR20170045365A (ko) 2017-04-26
KR102762958B1 true KR102762958B1 (ko) 2025-02-04

Family

ID=54207775

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177010086A Active KR102762958B1 (ko) 2014-09-15 2015-09-15 위장관췌장 신경내분비 신생물의 진단을 위한 조성물, 방법 및 키트
KR1020257003150A Pending KR20250021631A (ko) 2014-09-15 2015-09-15 위장관췌장 신경내분비 신생물의 진단을 위한 조성물, 방법 및 키트

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257003150A Pending KR20250021631A (ko) 2014-09-15 2015-09-15 위장관췌장 신경내분비 신생물의 진단을 위한 조성물, 방법 및 키트

Country Status (13)

Country Link
US (4) US10407730B2 (https=)
EP (2) EP3194618B1 (https=)
JP (2) JP6782700B2 (https=)
KR (2) KR102762958B1 (https=)
CN (1) CN107208132A (https=)
AU (3) AU2015317893B2 (https=)
CA (1) CA2959670C (https=)
DK (2) DK3929303T3 (https=)
ES (2) ES2881474T3 (https=)
IL (2) IL250867B (https=)
MX (2) MX386919B (https=)
PL (2) PL3929303T3 (https=)
WO (1) WO2016044330A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3194618B1 (en) 2014-09-15 2021-04-21 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
KR102763004B1 (ko) * 2017-05-25 2025-02-04 리퀴드 바이옵시 리서치 엘엘씨 흑색종의 검출 방법
KR20250123230A (ko) * 2017-11-30 2025-08-14 리퀴드 바이옵시 리서치 엘엘씨 유전자 발현 검정을 이용한 펩티드 수용체 방사선요법의 예측
CN108048564B (zh) * 2018-02-09 2021-03-05 中国科学院昆明动物研究所 人glt8d1基因的新用途
WO2020027732A1 (en) * 2018-07-30 2020-02-06 Agency For Science, Technology And Research Method and system for assessing fibrosis in a tissue sample
MX2022004372A (es) 2019-10-10 2022-07-27 Liquid Biopsy Res Llc Composiciones, métodos y kits para la estabilización de muestras biológicas y de arn.
FR3110764B1 (fr) * 2020-05-20 2024-05-10 Quantum Surgical Méthode de prédiction de la récidive d’une lésion par analyse d’images
CN113215255B (zh) * 2021-04-26 2022-04-05 山东天川精准医疗科技有限公司 用于肝癌早期诊断或预后的生物标记物及其用途
US20260021141A1 (en) * 2022-07-15 2026-01-22 Emendobio Inc. Strategies For Knock-Ins At APLP2 Safe Harbor Sites
KR20250080875A (ko) * 2022-09-30 2025-06-05 리퀴드 바이옵시 리서치 엘엘씨 타액에서 신경내분비암을 검출하는 방법
CN117292755B (zh) * 2023-08-09 2026-02-06 郑州大学 多模态临界边生物标志物识别方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014512172A (ja) * 2011-03-01 2014-05-22 イエール ユニバーシティ 胃腸膵神経内分泌新生物（ｇｅｐ−ｎｅｎ）の予測方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020795A2 (en) 2003-08-25 2005-03-10 The Johns Hopkins University Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differntial gene expression analysis
CA2727082C (en) * 2008-06-12 2019-02-26 Syntaxin Limited Fusion proteins for use in suppression of acromegaly
EP3194618B1 (en) 2014-09-15 2021-04-21 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014512172A (ja) * 2011-03-01 2014-05-22 イエール ユニバーシティ 胃腸膵神経内分泌新生物（ｇｅｐ−ｎｅｎ）の予測方法

Also Published As

Publication number Publication date
MX2021012347A (es) 2021-10-22
IL281355B (en) 2022-02-01
ES3013599T3 (en) 2025-04-14
DK3929303T3 (da) 2025-03-03
AU2021212151A1 (en) 2021-08-26
CA2959670C (en) 2024-02-20
IL250867B (en) 2021-03-25
US11168372B2 (en) 2021-11-09
US20160076106A1 (en) 2016-03-17
IL281355A (en) 2021-04-29
CN107208132A (zh) 2017-09-26
IL250867A0 (en) 2017-04-30
JP7157788B2 (ja) 2022-10-20
JP6782700B2 (ja) 2020-11-11
US20220325351A1 (en) 2022-10-13
EP3929303B1 (en) 2024-12-04
EP3194618A1 (en) 2017-07-26
WO2016044330A1 (en) 2016-03-24
JP2021019618A (ja) 2021-02-18
EP3929303A1 (en) 2021-12-29
AU2021212151B2 (en) 2023-08-03
EP3194618B1 (en) 2021-04-21
PL3194618T3 (pl) 2021-12-13
US10407730B2 (en) 2019-09-10
MX386919B (es) 2025-03-19
US20260043085A1 (en) 2026-02-12
KR20170045365A (ko) 2017-04-26
US20190345568A1 (en) 2019-11-14
JP2017528164A (ja) 2017-09-28
ES2881474T3 (es) 2021-11-29
AU2015317893B2 (en) 2021-05-20
AU2023258444A1 (en) 2023-11-23
BR112017005279A2 (pt) 2017-12-12
CA2959670A1 (en) 2016-03-24
KR20250021631A (ko) 2025-02-13
US12258633B2 (en) 2025-03-25
PL3929303T3 (pl) 2025-04-28
AU2015317893A1 (en) 2017-03-23
MX2017003370A (es) 2017-11-22
DK3194618T3 (da) 2021-07-12

Similar Documents

Publication Publication Date Title
US12258633B2 (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
AU2017204086B2 (en) Predicting gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)
CA3038743A1 (en) Classification and prognosis of cancer
WO2015073949A1 (en) Method of subtyping high-grade bladder cancer and uses thereof
HK40066027A (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
HK40066027B (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
HK1241416B (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
BR112017005279B1 (pt) Métodos para detectar um neoplasma neuroendócrino gastroenteropancreático (gep-nen), para diferenciar gep-nen estável de um gep-nen progressivo e para determinar uma resposta a uma terapia com radionucleotídeo para receptor de peptídeo de um gep-nen
HK1193127A (en) Evaluating response to therapy of gastroenteropancreatic neuroendocrine neoplasms (gep-nens)
HK1193127B (en) Evaluating response to therapy of gastroenteropancreatic neuroendocrine neoplasms (gep-nens)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PA0102 Application to register extension of term of patent right following delayed registration

St.27 status event code: A-4-4-G10-G15-tad-PA0102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 290

PR1102 Extension of patent period due to registration delay

St.27 status event code: A-4-4-G10-G17-tad-PR1102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 290

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000